|
Jul 24
|
Bonds Fall on Jobs Strength as Stocks Grind Higher: Markets Wrap
|
|
Jul 24
|
Sarepta Therapeutics (SRPT): “They Should Be Prosecuted,” Says Jim Cramer
|
|
Jul 24
|
Is This Stock a Buy After Soaring by 20% in 1 Day?
|
|
Jul 23
|
Sarepta stock faces multiple downgrades and questions of solvency amid Elevidys pause
|
|
Jul 23
|
Shopify and Unity downgraded: Wall Street's top analyst calls
|
|
Jul 23
|
Arrowhead Says Sarepta Expected to Meet Financial Obligations Despite Setbacks
|
|
Jul 23
|
Arrowhead Pharmaceuticals Issues Statement on the Status of its Ongoing Agreement with Sarepta Therapeutics
|
|
Jul 23
|
Sarepta’s Troubles Show Risk, Investor Opportunity in Biotech Convertible Bonds
|
|
Jul 22
|
Sarepta Makes A 'Painful' Decision. Will It Help Rebuild Investors' Confidence?
|
|
Jul 22
|
Arrowhead Pharma (ARWR) Shares Dragged by Sarepta Concerns
|
|
Jul 22
|
Why Sarepta's halted drug Elevidys is an issue for investors
|
|
Jul 22
|
Sarepta Faces Fresh Setback. Why Now’s Not the Time to Buy the Stock.
|
|
Jul 22
|
Sarepta shares slide again as drugmaker bows to FDA pressure to pause gene therapy
|
|
Jul 22
|
Sarepta falls after gene therapy maker pauses Elevidys shipments in US
|
|
Jul 22
|
Netflix downgraded, Intel initiated: Wall Street's top analyst calls
|
|
Jul 22
|
SRPT Slides on Voluntary US Elevidys Shipment Pause Amid Scrutiny
|
|
Jul 22
|
Morning Movers: Cleveland-Cliffs rallies after second quarter earnings release
|
|
Jul 22
|
Sarepta halts Elevidys shipments following FDA pressure
|
|
Jul 21
|
Sarepta Therapeutics Announces Voluntary Pause of ELEVIDYS Shipments in the U.S.
|
|
Jul 21
|
Sarepta under pressure: FDA requests halt of Elevidys shipments
|